Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies

PURPOSE: This phase I trial assessed the safety, maximally tolerated dose (MTD) and pharmacokinetics of TRKA/CDK inhibitor PHA-848125AC in adult patients with advanced/metastatic solid tumors. PATIENTS AND METHODS: Patients with relapsed or refractory solid tumors, for which no standard therapy exis...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Weiss, Glen J., Hidalgo, Manuel, Borad, Mitesh J., Laheru, Daniel, Tibes, Raoul, Ramanathan, Ramesh K., Blaydorn, Lisa, Jameson, Gayle, Jimeno, Antonio, Isaacs, Jeffrey D., Scaburri, Angela, Pacciarini, Maria Adele, Fiorentini, Francesco, Ciomei, Marina, Von Hoff, Daniel D.
Formato: Artigo
Idioma:Inglês
Publicado em: 2011
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3561458/
https://ncbi.nlm.nih.gov/pubmed/22160853
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-011-9774-6
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados